-61%

est. 2Y upside i

HealthcareSeries A

CRISPR powered Diagnostics with results in minutes.

Rank

#1466

Sector

Biotechnology / Molecular Diagnostics

Est. Liquidity

~5Y

Data Quality

Data: Medium

VedaBio presents a strong upside opportunity for a job seeker, driven by its breakthrough CRISPR-based molecular detection platform and a strategic partnership with Siemens Healthineers.

Last updated: March 10, 2026

Bull (30%)+300%

VedaBio's CRISPR Cascade platform achieves early regulatory approval and significant commercial traction, potentially through an expanded partnership with Siemens Healthineers or another major diagnostic player. This validates the amplification-free technology for rapid, highly multiplexed molecular detection, leading to a valuation of $1.2B within 2 years, driven by strong product pipeline and market adoption.

Base (25%)+50%

VedaBio continues to advance its product development and clinical validation, securing additional strategic partnerships and demonstrating promising early data. While commercialization is still a few years out, the technology's potential is further de-risked, leading to a modest valuation increase to $450M through a subsequent funding round or a smaller strategic investment.

Bear (45%)-80%

VedaBio faces significant regulatory hurdles, unexpected technical challenges in scaling its platform, or increased competitive pressure from incumbents developing similar amplification-free technologies. This could lead to delays, requiring a down round or a less favorable acquisition, resulting in a valuation of $60M, significantly impacting common stock value due to liquidation preferences.

Est. time to liquidity~5.0 years

Preference Stack Risk

high

Investors hold $65M in liquidation preferences, representing 21.67% of the estimated $300M valuation. In an exit at or below $65M, common stock would receive little to nothing.

Dilution Risk

high

As a clinical-stage biotech, VedaBio will likely require multiple large funding rounds before profitability or a major exit, leading to significant future dilution.

Secondary Liquidity

none

There is no active secondary market for shares of this early-stage private company.

Other — 1 role

View all 1 open roles at VedaBio →

Last updated: March 10, 2026

Questions to Ask at the Interview

Strategic questions based on VedaBio's data — designed to show you've done your homework.

  • 1

    “Given the strategic agreement with Siemens Healthineers, how is VedaBio planning to navigate potential conflicts of interest or competitive dynamics with other large diagnostic players, such as Roche or Abbott, as you bring products to market?”

  • 2

    “With a breakthrough platform but no current revenue, what are the key milestones and timelines for regulatory approval and initial commercialization of your CRISPR Cascade platform, particularly within the next 2-3 years?”

  • 3

    “Considering the very high capital intensity of biotech and the current Series A extension, what is the company's long-term funding strategy, and how do you anticipate managing potential future dilution for employees holding equity?”

Community

Valuation Sentiment

Our model estimates -61% upside. What do you think?

Anonymous. Do not share material non-public information.

Community Discussion

Comments are reviewed before they appear publicly.

0/2000

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.